IRIDEX (IRIX) Fundamentals 2026 — Revenue Analysis | SniperIQ
IRIDEX (IRIX) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is IRIDEX's market cap?
IRIDEX (IRIX) has a market capitalization of approximately
What is IRIDEX's P/E ratio?
IRIDEX's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is IRIDEX?
IRIDEX runs a net profit margin of -6.2%, a gross margin of 36.1%, and an operating margin of -5.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does IRIDEX generate?
IRIDEX reported revenue of $53M for fiscal year 2025, with net income of -$4M and earnings per share (EPS) of -0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does IRIDEX pay a dividend?
IRIDEX does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is IRIDEX financially healthy?
IRIDEX carries a debt-to-equity ratio of 0.90x and a current ratio of 1.92x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is IRIDEX a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For IRIDEX (IRIX) the key facts are: market cap
Track IRIDEX's full fundamentals live
Get IRIDEX's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.